AAV1-hOTOF gene therapy for autosomal recessive deafness | The Lancet
Date : 2024-01-24
Abstract
Autosomal recessive deafness 9, caused by mutations of the OTOF gene, is characterised by congenital or prelingual, severe-to-complete, bilateral hearing loss. However, no pharmacological treatment is currently available for congenital deafness. In this Article, we report the safety and efficacy of gene therapy with an adeno-associated virus (AAV) serotype 1 carrying a human OTOF transgene (AAV1-hOTOF) as a treatment for children with autosomal recessive deafness 9.
Research paper below
Recently on :
DNA | Evolution
Health | Healthcare
WEB - 2024-02-01
Evolution: Fast or Slow? Lizards Help Resolve a Paradox | Quantamagazine
Quantamagazine - Carrie Arnold reports on a study of lizard species in Miami that reveals how short-term variability can lead t...
WEB - 2024-01-24
AAV1-hOTOF gene therapy for autosomal recessive deafness | The Lancet
The Lancet - Jun Lv, Hui Wang, Xiaoting Cheng, Yuxin Chen, Daqi Wang, Longlong Zhang, Qi Cao, Honghai Tang, Shaowei Hu, Kaiyu ...
WEB - 2023-11-23
Uncovering the functional diversity of rare CRISPR-Cas systems with deep terascale clustering
Han Altae-Tran, Soumya Kannan , Anthony J Suberski, Kepler S Mears, F Esra Demircioglu, Lukas Moeller, Selin Kocalar, Rachel Os...
WEB - 2023-10-23
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
Verve Therapeutics, a clinical-stage biotechnology company, announced the lifting of the clinical hold and clearance of its IND...
WEB - 2023-10-06
Could Earth be the only planet with intelligent life? | Big Think
Big Think - Ethan Siegel explains what the science has to say about the possibility that planet Earth is home to the only insta...